[Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study].

[1]  G. Valdivia,et al.  Diagnostic labeling of COPD in five Latin American cities. , 2007, Chest.

[2]  J. Jardim,et al.  Valores de referencia espirométrica en 5 grandes ciudades de Latinoamérica para sujetos de 40 o más años de edad , 2006 .

[3]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[4]  A. Torres,et al.  Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.

[5]  Cesar G Victora,et al.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study , 2005, The Lancet.

[6]  S. Uh,et al.  Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. , 2005, American journal of respiratory and critical care medicine.

[7]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[8]  A. Agustí,et al.  COPD, a multicomponent disease: implications for management. , 2005, Respiratory medicine.

[9]  J. Díez,et al.  Factores determinantes de la prescripción farmacológica en los pacientes con EPOC estable. Resultados de un estudio multicéntrico español (IDENTEPOC) , 2005 .

[10]  J. Hankinson,et al.  SERIES ''ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING'' Edited by V. Brusasco, R. Crapo and G. Viegi Number 2 in this Series Standardisation of spirometry , 2005 .

[11]  C. Victora,et al.  The Platino project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities , 2004, BMC medical research methodology.

[12]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[13]  V. Peña,et al.  Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional , 2004 .

[14]  John E Connett,et al.  Smoking and lung function of Lung Health Study participants after 11 years. , 2002, American journal of respiratory and critical care medicine.

[15]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[16]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[17]  M. Miravitlles.  Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[18]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[19]  N. Roche,et al.  Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease , 2001, European Respiratory Journal.

[20]  A. Agustí,et al.  Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica , 2001 .

[21]  P. Poole,et al.  Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review , 2001, BMJ : British Medical Journal.

[22]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[23]  Christine Jenkins,et al.  GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY , 2001 .

[24]  M. Fiore.  US public health service clinical practice guideline: treating tobacco use and dependence. , 2000, Respiratory care.

[25]  M. Miravitlles,et al.  Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. , 2000, Chest.

[26]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[27]  S. Ramsey.  Suboptimal medical therapy in COPD: exploring the causes and consequences. , 2000, Chest.

[28]  M. Rudolf.  The reality of drug use in COPD: the European perspective. , 2000, Chest.

[29]  K. Nichol,et al.  Relation between Influenza Vaccination and Outpatient Visits, Hospitalization, and Mortality in Elderly Persons with Chronic Lung Disease , 1999, Annals of Internal Medicine.

[30]  BTS Guidelines for the Management of Chronic Obstructive Pulmonary Disease , 1997, Thorax.

[31]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[32]  P. Sly,et al.  Allergic respiratory disease: strategic targets for primary prevention during childhood. , 1997, Thorax.

[33]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[34]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[35]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[36]  A. Buist.  Standardization of spirometry. , 1987, The American review of respiratory disease.